Cendakimab (RPC4046; ABT 308; CC-93538) is a selective humanized recombinant monoclonal antibody targeting the IL-13 molecule with high specificity. It demonstrates potent affinity for both the wild-type and variant forms of human IL-13, effectively inhibiting IL-13's interaction with its receptors, IL-13Rα1 and IL-13Rα2, as evidenced by IC50 values of 352 pM and 631 pM, respectively, determined via ELISA. Furthermore, Cendakimab binds with comparable affinities of 52 pM and 50 pM to the wild-type human IL-13 and its common R110Q polymorphic variant. This antibody holds therapeutic potential for treating IL-13-related allergic and inflammatory conditions, such as asthma and eosinophilic esophagitis.